Adverum Biotechnologies to Present at the 2018 Jefferies Global Healthcare Conference
|Event:||Jefferies Global Healthcare Conference|
|Date:||June 8, 2018|
|Time:||12:30 – 12:55 p.m. ET|
|Location:||New York, NY|
A live and replay audio webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Leone PattersonInterim President and Chief Executive Officer 650-665-7222 firstname.lastname@example.org
Source: Adverum Biotechnologies, Inc.